Bert Klebl, CEO & CSO at LDC, has gathered more than 15 years of professional experience in the life sciences/pharmaceutical industry. He has worked in different positions in drug discovery and early development. He is in his current role at LDC since early 2008. Most recently he was Senior Director Discovery Biology and Head of Biology at GPC Biotech. Previously he was Axxima’s Vice President Research and as such responsible for the discovery and development of the company’s portfolio of kinase inhibitors for various therapeutic indications. In former positions, he has worked as a project and platform manager primarily on a kinase inhibitor program, as well as a scientist at Aventis and Hoechst Marion Roussel. He earned his PhD in biochemistry at the University of Konstanz, Germany, and did postdoctoral work at the NRC Biotechnology Research Institute in Montréal, Canada. In the course of his research, he has published more than 30 articles in peer-reviewed journals and is a co-inventor of more than 20 patents and patent applications. He is scientific advisory board member of CI3, EMD and Vichem Kft. In addition he served as an expert panel reviewer for translation research centers, e.g. CDRD, Vancouver/Canada and IP-K, Seoul/South Korea.